| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
and Retinoid X Receptor Heterodimer
National Research Laboratory, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea
| ABSTRACT |
|---|
|
|
|---|
(PPAR
) and the retinoic acid X receptor (RXR) play roles in regulating cell differentiation and chemoprevention. This study examined GSTA2 gene induction by the PPAR
activator and 9-cis-retinoic acid (RA), a RXR ligand, and investigated the molecular basis of PPAR-RXR-mediated GSTA2 induction in the H4IIE hepatocytes. Either 15-deoxy-
(12, 14)-prostaglandin J2 (PGJ2) or RA induced GSTA2 with Nrf2 and C/EBPß activation. When compared with PGJ2 or RA alone, PGJ2 + RA enhanced GSTA2 induction, with increases in Nrf2 and C/EBPß activation. PGJ2 + RA increased the luciferase reporter gene activity in the cells transfected with the 1.65-kb flanking region of the GSTA2 gene. Thiazolidinedione PPAR
agonists, troglitazone, rosiglitazone, and pioglitazone, in combination with RA, potentiated GSTA2 induction, confirming that the activation of the PPAR
and RXR heterodimer contributed to GSTA2 expression. Deletion of the antioxidant response element- or C/EBP-binding sites or the overexpression of dominant-negative mutant of C/EBP abolished the reporter gene expression. PGJ2 + RA increased the binding of the PPAR
RXR heterodimer to the putative PPAR-response elements (PPREs) in the GSTA2 promoter. Specific mutations of these multiple PPRE sites resulted in the complete loss of its responsiveness to PGJ2 + RA, which suggests that these binding sites function as a PPRE-responsive enhancer module (PPREM). Transactivation of PPREM by the PPAR
RXR heterodimer was verified by the effective GSTA2 induction in the cells treated with PGJ2 + RA after transfecting them with the plasmids encoding PPAR
1 and RXR
. In conclusion, the PPAR
RXR heterodimer promotes GSTA2 induction by activating PPREM in the GSTA2 gene, as well as inducing Nrf2 and C/EBPß activation. | INTRODUCTION |
|---|
|
|
|---|
The activation of the antioxidant response element (ARE) by reactive oxygen species from prooxidants contributes to the regulation of Phase II enzymes, including the GSTs (2
, 3)
. The signals activated by oxidative stress stimulate the transduction of NF-E2-related factor (Nrf) activity and ARE activation (4
, 5) . The protein binding to the ARE consensus sequence involves the Nrf proteins, as well as Maf family members (6
, 7)
. Oxidative stress induces GSTA2 via ARE activation, which involves the Nrf proteins (8
, 9)
. Transcription factors of the CCAAT/enhancer binding protein (C/EBP) family play roles in cell differentiation and exert their function by regulating the expression of tissue-specific genes, as well as cell proliferation (10
, 11)
. In response to growth stimuli, the members of the C/EBP family involved in the transcription of the tissue-specific genes include C/EBPß and C/EBP
(12)
. C/EBP constitutes an essential distinct pathway for GST induction. Previous studies have shown that C/EBPß activation and its binding to the C/EBP-response element plays a crucial role in the induction of the GSTA2 gene (13
, 14)
.
The peroxisome proliferator-activated receptors (PPARs) are well-characterized transcription factors that are members of the nuclear hormone receptor superfamily (15)
. There are three PPARs subtypes, including PPAR
, PPARß, and PPAR
, which have distinct distribution patterns. PPAR
is mainly present in the liver, heart, and kidney, whereas PPARß is expressed ubiquitously (15)
. PPAR
is predominantly expressed in the adipose tissue and, to a lesser extent, in the liver (15)
. PPAR
activators up-regulate the expression of the genes involved in adipocyte differentiation (16)
. Although the basal expression of the PPAR
in the liver is relatively low, hepatic PPAR
is pronouncedly up-regulated by PPAR
activators and under certain pathophysiological conditions (e.g., obesity) for the activation of several PPAR
-responsive genes (17
, 18)
. PPAR
is also an important target for the development of new drugs aimed at preventing and treating cancer. A deficiency in PPAR
expression can be a significant risk factor for carcinogenesis (19)
. Ligands for PPAR
suppress carcinogenesis in experimental models and induce the differentiation of human tumorigenic cells (20, 21, 22, 23)
. The activated PPAR
forms a heterodimer with retinoid X receptor (RXR)
and binds to specific PPAR response elements in the promoter region of their target genes (24)
. Therefore, PPAR
agonists affect cell survival, growth, and differentiation by binding to the peroxisomal proliferator-response element (PPRE).
Hepatic stellate cells in the liver contain 4070% of the body stores of retinoids. Retinoic acids, which are natural metabolites of circulating vitamin A, are essential for maintaining the normal pathway of epithelial tissues differentiation (25)
. Natural and synthetic retinoids are also effective in preventing a variety of cancers in animals and in reversing preneoplastic lesions in humans (26, 27, 28, 29)
. A large-scale study of the cancer chemopreventive role of retinoic acids in human has shown that retinoids exhibit a high degree of specificity in cancer chemoprevention (30)
. The major retinoids responsible for the transcriptional regulation of many processes in the development and differentiation are all-trans and 9-cis-retinoic acids (RAs), which affect the important biological processes via their interaction with the nuclear receptors (25)
. In particular, RA was identified as an activating ligand that is relatively selective for RXR
, which must heterodimerize with a permissive partner (24
, 31
, 32)
. RXR
is essential for the high-affinity DNA binding of PPAR and serves as an auxiliary DNA-binding factor.
From these observations, it is possible that PPAR
and RXR
agonists activate the expression of the liver-specific genes at the transcriptional level. The liver-specific target genes may include GSTs because there is an extremely high (i.e.,
10 mM) concentration of glutathione in the liver. The conjugation of xenobiotics with glutathione, which are catalyzed by all classes of GSTs, is fundamentally different from their conjugation with other amino acids, because the substrates of glutathione conjugation include an enormous range of electrophilic xenobiotics or xenobiotics, which are biotransformed to electrophiles (33)
. The GSTA2 gene is a representative member of the class
GSTs that contains a xenobiotic-response element, putative phenobarbital-responsive element, glucocorticoid-responsive element, and an ARE. However, no functionally active PPRE or PPRE-responsive enhancer module (PPREM) has yet been identified in the GSTA2 gene. In the present study, we initially found the putative multiple PPREs in the promoter region of the GSTA2 gene. We determined whether the PPAR
and RXR activators induce GSTA2 via activating PPAR
RXR heterodimer binding to the putative PPREs in H4IIE hepatocytes and, if so, whether the putative PPREs function as a module where there needs to be multiple nuclear binding sites in close proximity. We used 15-deoxy-
(12
, 14)
-prostaglandin J2 (PGJ2) and thiazolidinedione PPAR
ligands as the PPAR
agonists. It was found that the combined treatment of the PPAR
agonist and RA both activated and induced Nrf2 and C/EBPß, which are the essential transcription factors for GSTA2 expression. More importantly, the PPAR-binding site cluster in the GSTA2 gene was identified as a functionally active PPREM.
| MATERIALS AND METHODS |
|---|
|
|
|---|
-32P]dCTP (3000 mCi/mmol) and [
-32P]ATP (3000 mCi/mmol) were purchased from New England Nuclear (Arlington Heights, IL). The random prime-labeling kit was supplied by Promega (Madison, WI). PGJ2 and troglitazone were purchased from Biomol Research Labs (St. Louis, MO). Pioglitazone and rosiglitazone were kindly supplied from Dong-A Pharmaceutical Co. (Shingal, Korea). RA, DTT, and 3-[N-morpholino]propanesulfonic acid were provided from Sigma Chemical (St. Louis, MO). Anti-PPAR
antibody and anti-RXR
antibody were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The plasmid pGTB-1.65 construct containing the GSTA2-promoter region (1651 to +66 bp from the transcription start site) was kindly provided by Dr. C. B. Pickett (Schering-Plough Corp. Inst., Kenilworth, NJ), and the C/EBP dominant-negative expression (AC/EBP) plasmid was a gift from Dr. C. Vinson (NIH, Besthesda, MD; Ref. 34
). AC/EBP prevents the "normal" C/EBP from binding to DNA because C/EBP acts as a dimer. The expression plasmid of mouse PPAR
1 (i.e., pCMX-mPPAR
1) was kindly supplied from Dr. C. K. Glass (University of California, San Diego, CA). The human RXR
expression plasmid (PECE-RXR
) was provided by Dr. M. O. Lee (Sejong University, Seoul, Korea).
Construction of Plasmids.
The pGL-1651 reporter gene construct containing the promoter region of the GSTA2 gene was generated according to methods described previously (14)
. Briefly, the region containing 1651 to +66 bp of the GSTA2 gene was amplified by PCR using pGTB-1.65 as a template. The PCR product was cloned into pGEM-T EasyVector (Promega) and subcloned into the pGL3 luciferase reporter plasmid. The deletion mutants of GSTA2 promoter-luciferase plasmid, pGL-
C/EBP and pGL-
ARE, in which the C/EBP binding site and ARE were deleted, respectively, were constructed by PCR-based methods. The specific PPRE mutant constructs of the GSTA2 promoter-luciferase reporter gene, pGL-mPPRE1, pGL-mPPRE2, and pGL-mPPRE3, were prepared by replacing the respective direct repeat (DR)1 site with 5'-CTCGAGAGAATTC-3'. The mutant plasmids were generated by the overlapping PCR technique and then ligated into the pGL3 plasmid. To increase RXR
expression, the coding region of RXR
derived from PECE-RXR
(HindIII and EcoRI digestion) was subcloned into pCDNA3.1 (Invitrogen, Carlsbad, CA; i.e., pCDNA-RXR
). The DNA sequences of the constructs were verified by sequence analysis using an ABI7700 DNA cycle sequencer.
Cell Culture.
H4IIE, a rat hepatocyte-derived cell line, and 3T3-L1, a murine preadipocyte cell line, were obtained from American Type Culture Collection (Rockville, MD). Cells were maintained in DMEM containing 10% FCS, 50 units/ml penicillin, and 50 µg/ml streptomycin at 37°C in a humidified atmosphere with 5% CO2. 3T3-L1 preadipocytes were differentiated to adipocytes by incubating in the medium containing 10% FCS, 1 µM dexamethasone, 1 µg/ml insulin, and 0.5 mM 3-isobutyl-1-methylxanthine, as described previously (35)
. Hepatic stellate cells and primary hepatocytes were isolated from male Sprague Dawley rats according to the method published previously with slight modifications (36)
.
PPAR
Agonist and RA Treatment.
PGJ2, troglitazone, pioglitazone, rosiglitazone, and RA, dissolved in DMSO, were added to H4IIE cells and incubated for the indicated time period for each experiment at 37°C. Cells were then washed twice with ice-cold PBS before sample preparation.
Preparation of a cDNA Probe for GSTA2.
A cDNA probe for the GSTA2 gene was amplified by reverse transcription-PCR using selective primers (37)
and cloned in the pGEM-T vector (Promega).
Preparation of Nuclear Extracts.
Nuclear extracts were prepared according to methods published previously (14)
. Briefly, H4IIE cells in dishes were washed twice with ice-cold PBS and then scraped from the dishes with PBS and transferred to microtubes. Cells were then centrifuged at 2,500 x g for 3 min and allowed to swell after the addition of 100 µl of hypotonic buffer containing 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.5% NP40, 1 mM DTT, and 0.5 mM phenylmethylsulfonylfluoride. The lysates were incubated for 10 min on ice and then centrifuged at 7,200 x g for 5 min at 4°C. Pellets containing crude nuclei were resuspended in 50 µl of extraction buffer containing 20 mM HEPES (pH 7.9), 400 mM NaCl, 1 mM EDTA, 10 mM DTT, and 1 mM phenylmethylsulfonyl fluoride and then incubated for 30 min on ice. The samples were then centrifuged at 15,800 x g for 10 min to obtain supernatants containing nuclear fractions. Nuclear fractions were stored at 70°C until use.
Preparation of Cytosolic Fractions.
H4IIE cells were washed twice with sterile PBS, scraped from their dishes, and sonicated to disrupt the membranes. Cytosolic fractions were prepared by differential centrifugation at 15,000 x g for 15 min and stored at 70°C until use. Protein content was determined by the Bradford assay (Bio-Rad protein assay kit; Bio-Rad, Hercules, CA).
Northern Blot Analysis.
Total RNA was isolated from H4IIE cells using the single-step method of thiocyanate-phenol-chloroform RNA extraction, and Northern blot analysis was carried out according to procedures described previously (37)
. Briefly, total RNA was resolved by electrophoresis in a 1% agarose gel containing 2.2 M formaldehyde and transferred to nitrocellulose paper. The nitrocellulose paper was baked in a vacuum oven at 80°C for 2 h. The filter was then incubated with hybridization buffer containing 50% deionized formamide, 5 x Denhardts solution [0.1% Ficoll, 0.1% polyvinylpyrrolidine, and 0.1% BSA (Pentex Fraction V)], 0.1% SDS, 200 µg/ml sonicated salmon sperm DNA, and 5 x saline-sodium phosphate-EDTA [1 x saline-sodium phosphate-EDTA = 0.15 M NaCl, 10 mM NaH2PO4, and 1 mM Na2EDTA (pH 7.4)] at 42°C for 1 h without probe. Hybridization was performed at 42°C for 18 h with a heat-denatured cDNA probe for GSTA2 that was random prime-labeled with [
-32P]dCTP. Filters were washed twice in 2 x SSC (1 x SSC = 150 mM NaCl and 15 mM sodium citrate) and 0.1% SDS for 10 min at room temperature and twice in 0.1 x SSC and 0.1% SDS for 10 min at room temperature. Filters were then washed once in a solution containing 0.1 x SSC and 0.1% SDS for 1 h at 60°C. After quantitation of GSTA2 mRNA levels via scanning densitometry, the membranes were stripped and rehybridized with a 32P-labeled cDNA probe for 18S rRNA to control for RNA loading onto the membranes. Four separate experiments were performed with different RNA samples.
Immunoblot Analysis.
SDS-PAGE and immunoblot analysis were performed according to procedures published previously (37)
. Briefly, proteins were separated by 7.5 or 12% gel electrophoresis and electrophoretically transferred to nitrocellulose paper. The replicate SDS-PAGE gels were stained with Coomassie Blue for verification of equal loading of proteins before immunoblotting. The nitrocellulose paper was incubated with an anti-GST
antibody (Detroit R&D, Detroit, MI), followed by incubation with a horseradish peroxidase-conjugated secondary antibody. Specificity of the antibodies to the GST subunit has been confirmed previously (8
, 37)
. Immunoreactive protein was visualized through incubation with an enhanced chemiluminescence detection kit (Amersham Biosciences, Buckinghamshire, United Kingdom; Ref. 8
). Equal loading of proteins was verified by actin immunoblotting with a goat antiactin antibody (Santa Cruz Biotechnology). Three or four separate experiments were performed with different cytosolic samples. Changes in the levels of GSTA2 protein in the cells treated with PPAR
agonist + RA relative to that in untreated control were determined via scanning densitometry. Similarly, PPAR
, Nrf2, and C/EBPß were immunochemically detected with their respective antibodies (Santa Cruz Biotechnology). At least three separate experiments were performed with different subcellular fractions (or lysates) to confirm changes in the protein levels.
Scanning Densitometry.
Scanning densitometry of the Northern and immunoblots was performed with Image Scan & Analysis System (Alpha-Innotech Corp., San Leandro, CA). The area of each lane was integrated using the software AlphaEase version 5.5, followed by background subtraction.
Gel Shift Assay.
A double-stranded DNA probe containing the GSTA2 gene ARE end-labeled with [
-32P]ATP, and T4 polynucleotide kinase was used for gel shift analysis. The sequence of the ARE-containing oligonucleotide was 5'-GATCATGGCATTGCACTAGGTGACAAAGCA-3'. Similarly, C/EBP gel shift analysis was carried out with the radiolabeled oligonucleotide, 5'-TGCAGATTGCGCAATCTGCA-3', which contained the C/EBP consensus sequence. The consensus PPRE sequence was 5'-CCAAGGTCAAAGGTCATGT-3'. To study the binding of nuclear hormone receptors to the DNA-binding sites, double-stranded PPRE oligonucleotides derived from PPRE1, 5'-CCATCGGTGATGACCTTGT-3'; PPRE2, 5'-TTGGCAGGAAGGATCAGTA-3'; and PPRE3, 5'-AACAGGACAAAGATTAAGA-3' present in the promoter region of the GSTA2 gene were used as probes. The reaction mixture contained 4 µl of 5 x binding buffer [containing 50 mM Tris-Cl (pH 7.5), 20% glycerol, 5 mM MgCl2, 250 mM NaCl, 2.5 mM EDTA, 2.5 mM DTT, and 0.25 mg/ml poly dI-dC], 10 µg of nuclear extract, and sterile water up to a total volume of 20 µl. The reaction mixture was preincubated without probe at room temperature for 10 min. The probe (1 µl, containing 106 cpm) was then added, and DNA-binding reactions were carried out for 30 min at room temperature. In some analyses, specificity of binding was determined by competition experiments, which were carried out by adding a 10-fold molar excess of an unlabeled ARE, C/EBP, or PPRE oligonucleotide to the reaction mixture before the labeled probe was added. SP-1 oligonucleotide (5'-ATTCGATCGGGGCGGGGCGAGC-3') was used as a negative control for competition experiments. In other analyses, known as immuno-inhibition assays, antibodies directed to Nrf2, C/EBP
, C/EBPß, PPAR
, and RXR
(2 µg each) were added to the reaction mixture 20 min after the labeled probe was added, and the reaction was then continued for 1 h at 25°C. Samples were separated on 4% polyacrylamide gels at 100 V. The gels were fixed with 40% methanol/10% acetic acid, dried, and subject to autoradiography.
Luciferase Reporter Gene Analysis.
We used the dual-luciferase reporter assay system (Promega). Briefly, H4IIE cells (7 x 105 cells/well) were replated in six-well plates overnight, serum starved for 12 h, and transiently transfected with each GSTA2 promoter-luciferase construct and pRL-SV plasmid (a plasmid that encodes for Renilla luciferase and is used to normalize transfection efficacy) in the presence of LipofectAMINE Plus Reagent (Life Technologies, Inc. Gaithersburg, MD) for 3 h. Transfected cells were incubated in DMEM containing 1% FCS (Life Technologies) for 3 h and exposed to PGJ2 + RA (50 nM each) in medium containing 10% FCS for 18 h at 37°C. Firefly and Renilla luciferase activities in cell lysates were measured using a Luminoskan luminometer (Thermo Labsystems, Helsinki, Finland). The activity of firefly luciferase was measured by adding Luciferase Assay Reagent II (Promega) according to the manufacturers instruction, and, after quenching the reaction, the Renilla luciferase reaction was initiated by adding Stop & Glo reagent (Promega). The relative luciferase activity was calculated by normalizing firefly luciferase activity to that of Renilla luciferase.
Statistical Analysis.
Scanning densitometry was performed with Image Scan & Analysis System (Alpha-Innotech). One-way ANOVA procedures were used to assess significant differences among treatment groups. For each significant effect of treatment, the Newman-Keuls test was used for comparisons of multiple group means. The criterion for statistical significance was set at P < 0.05 or <0.01. All statistical tests were two sided.
| RESULTS |
|---|
|
|
|---|
1 expression level was higher than that of PPAR
2 in most tissue types (15)
. To examine the role of PPAR
in GSTA2 expression, we first assessed the PPAR
levels in H4IIE hepatocytes and other representative cells. Immunoblot analysis revealed that mainly PPAR
1 was expressed in H4IIE cells (Fig. 1
1 was also expressed in the primary cultured hepatocytes or stellate cells isolated from the rat liver (Fig. 1
expression level was high in adipocytes (
1 is expressed to a greater extent than
2) but not in the preadipocytes,16 which was also confirmed by immunoblot analysis (Fig. 1
|
, induced GSTA2 in H4IIE cells. PGJ2, at concentrations of 300 or 1000 nM, increased the GSTA2 protein levels (Fig. 2A)
|
GSTA2 Induction by RA.
Next, we determined whether RA could induce GSTA2. Treatment of the H4IIE cells with RA (10300 nM), a ligand of RXR, for 24 h increased the GSTA2 protein level in a concentration-dependent manner (Fig. 3A)
. RA at concentrations of 100 or 300 nM induced GSTA2 23-fold with the maximum induction being observed at 300 nM. A time course study showed that RA gradually induced the GSTA2 protein level from 6 h with the maximum increase being noted at 24 h. Northern blot analyses confirmed that the level of GSTA2 mRNA increased after exposure of cells to 300 nM RA (Fig. 3B)
. The GSTA2 mRNA level peaked at 12 h.
|
, and RXR
indicated that an increase in the Nrf2-ARE DNA-binding activity by RA was dependent on Nrf2 (Fig. 3C)
Synergistic Induction of GSTA2 by PGJ2 + RA.
PPAR
heterodimerizes with the RXR for activation, and the PPAR
RXR heterodimers are widely expressed in the major organs, including the liver (15)
. We determined whether PGJ2 + RA enhanced GSTA2 induction. GSTA2 was induced 2-fold by 100 nM RA but not 100 nM PGJ2. In contrast to the weak induction of GSTA2 by each agent alone, PGJ2 + RA (100 nM each) synergistically increased the GSTA2 protein level (Fig. 4A)
. A preliminary study reported that PGJ2 + RA induced GSTA2 to the greatest extent at the 1:1 molar ratio. To determine the dose-response effect, the GSTA2 level was further assessed in the cells treated with PGJ2 + RA each at equal concentrations (i.e., 15, 50, or 100 nM) for 24 h (Fig. 4B)
. The dose-response study revealed that GSTA2 induction was efficaciously increased by the PGJ2 + RA treatment (i.e., 34-fold increases at concentrations of 15 or 50 nM). Therefore, 50 nM PGJ2 and RA each were selected for the subsequent experiments.
|
agonists in combination with RA on the GSTA2 expression. Immunoblot analysis revealed that troglitazone (110 µM) + RA (50 nM) synergistically induced GSTA2, whereas either troglitazone (110 µM) or RA alone only weakly increased the GSTA2 protein level (Fig. 5A)
and RXR heterodimer leads to the induction of GSTA2.
|
and RXR heterodimer induces GSTA2 in normal cells. Because the enhancement effect for GSTA2 expression by the PPAR
agonist was saturated at 10 µM in H4IIE cells, 1 or 3 µM the PPAR
agonist were chosen for this experiment. Troglitazone, rosiglitazone, or pioglitazone in combination with RA induced GSTA2 to a greater extent when compared with the PPAR
agonist alone at the concentrations examined (Fig. 5B)
and RXR heterodimer enhance GSTA2 expression in hepatocytes.
Activation of Nrf2 and C/EBPß by PGJ2 + RA.
To confirm that PGJ2 + RA (50 nM each) activates Nrf2, immunoblot and gel shift assays were performed with the nuclear extracts of the cells treated with PGJ2 + RA. PGJ2 + RA increased the nuclear Nrf2 levels and its binding to a radiolabeled ARE consensus oligonucleotide at 612 h. Binding of the protein to the ARE was competed with an excess amount of unlabeled ARE (Fig. 6A)
. Immunoblot and gel shift analyses showed that the PGJ2 + RA treatment increased the C/EBPß levels in the nuclear fractions and C/EBPß binding to the C/EBP binding oligonucleotide compared with the control (Fig. 6B)
. Competition experiments using excess quantities of unlabeled C/EBP or SP-1 oligonucleotides confirmed the specificity of C/EBP DNA binding. Supershift experiments indicated that the C/EBP-binding complex comprised of C/EBPß (Fig. 6B)
. The band intensity of C/EBP DNA-binding complex was reduced by the anti-C/EBPß antibody but not the anti-PPAR
or -RXR
antibodies. Immunocytochemistry confirmed that Nrf2 and C/EBPß, which were located mainly in the cytoplasm of control cells, had perinuclear and nuclear localization at 612 h in the cells treated with PGJ2 + RA, suggesting that these transcription factors translocate into the nucleus (data not shown).
|
|
|
ARE, which is a chimeric gene construct with the ARE deleted (Fig. 8A)
ARE, compared with that in the cells transfected with pGL-1651 (Fig. 8B)
C/EBP (Fig. 8B)
Binding of the PPAR
and RXR Heterodimer to the PPREs.
Studies have shown that PPAR
heterodimerizes with RXR (probably RXR
), which is activated by RA (38
, 39)
. Searching the GSTA2 promoter region with the PPRE consensus sequence, AGGTCANAGGTCA, resulted in three putative response elements (i.e., PPRE1, PPRE2, and PPRE3), to which the activating PPAR
RXR heterodimer might bind. The putative PPRE1 sequence present at 792 bp from the transcription start site contained a reverse DR1 site, whereas the other DR1 sites named PPRE2 and PPRE3 were present at 746 and 549 bp, respectively (Fig. 9A)
.
|
antibody or anti-RXR
antibody (Fig. 9E)
RXR heterodimer binding to the other PPREs was also confirmed by immunodepletion and competition analyses with the unlabeled oligonucleotides (data not shown).
Functional Analysis of the PPREs in the GSTA2 Promoter.
When the PPRE1 sequence located between the nucleotides 792 and 781 bp in pGL-1651 was mutated (Fig. 10A
; i.e., pGL-mPPRE1), the inducible luciferase activity by PGJ2 + RA was completely reduced to that of the control (Fig. 10B)
. For comparison, this study determined the effect of 3-methylcholanthrene, an AhR-xenobiotic-response element-mediating GSTA2 inducer, on the expression of pGL-mPPRE1 promoter reporter gene. Exposure of the H4IIE cells transfected with pGL-mPPRE1 to 3-methylcholanthrene increased the luciferase activity 8-fold compared with the untreated control (Fig. 10B)
. The increase in luciferase activity was comparable with that in pGL-1651-transfected cells treated with 3-methylcholanthrene. These results indicated that the PPRE1 in the GSTA2 gene is selectively activated by PGJ2 + RA. The role of the PPRE2 or PPRE3 site in responsiveness was also examined using mutation analyses (Fig. 10A)
. Mutation of each of the PPRE sites almost completely abolished the inducible expression of the pGL-1651 luciferase chimeric gene by PGJ2 + RA (Fig. 10C)
. Either pGL-mPPRE2 or pGL-mPPRE3 also responded to 3-methylcholanthrene. These results demonstrate that PGJ2 + RA directly activates the PPRE enhancer activities in the GSTA2 gene and that the multiple PPRE-binding sites are essential for the full ligand responsiveness.
|
1 RXR
Overexpression on the GSTA2 Transactivation.
1 and RXR
overexpression with or without ligands on the Nrf2, C/EBPß, and GSTA2 gene expression. The H4IIE cells were transfected with the plasmids encoding PPAR
1 and RXR
, which were then exposed to PGJ2 + RA. Either PPAR
1 or RXR
alone elicited a modest increase in the Nrf2 expression level. The concomitant expression of PPAR
1 and RXR
to the larger extent enhanced the level of Nrf2 level in the total cell lysates (Fig. 11A
1 and RXR
plasmids. Similarly, PPAR
1 and RXR
overexpression caused an increase in the C/EBPß level in the total cell lysates. C/EBPß was further induced by PGJ2 + RA in the cells transfected with the plasmids (Fig. 11A
|
selective agonists with or without RA to confirm that the ligand activation of PPAR
and RXR led to Nrf2 or C/EBPß. RA (50 nM), pioglitazone, or rosiglitazone alone (3 µM) failed to induce Nrf2 in the cell lysates. As expected, an increased Nrf2 expression level was noted in the cells treated with pioglitazone + RA or rosiglitazone + RA (Fig. 11A
The extents of protein binding to the PPRE-binding sites in the GSTA2 gene were next determined. PPAR
1 and RXR
overexpression in the H4IIE cells resulted in an increase in the band intensity of protein binding to PPRE3, which was enhanced by the PGJ2 + RA treatment (Fig. 11B)
. The addition of either the anti-PPAR
or -RXR
antibodies decreased the intensity of the shifted band, indicating that the binding proteins include PPAR
and RXR
.
To examine the effect of the PPAR
and RXR heterodimer on transactivation of the GSTA2 gene, functional reporter gene analysis was performed on the cells transfected with pGL-1651. The functional role of the PPAR
and RXR heterodimer in responsiveness was verified by an increase in the luciferase inducibility (Fig. 11C)
. The luciferase activity in the cells transfected with the plasmids encoding PPAR
1 and RXR
was comparable with that of the control cells treated with PGJ2 + RA. The luciferase reporter gene expression level was further increased after exposing the cells transfected with the PPAR
1 and RXR
plasmids to PGJ2 + RA (Fig. 11C)
. The results demonstrate that the PPAR
and RXR heterodimer, which interacts with the multiple PPRE-binding sites, makes crucial contribution to the inducible expression of the GSTA2 gene.
| DISCUSSION |
|---|
|
|
|---|
, PPARß/
, and PPAR
, constitute a subfamily of the nuclear receptor superfamily activated by a variety of natural and chemical ligands. The PPAR genes are involved in regulating the lipid metabolism (40, 41, 42)
. The RXRs, as members of the nuclear receptor superfamily, are the common heterodimeric partner for many receptors, including PPAR. The RXRs are modular proteins with a highly conserved central DNA-binding domain and less conserved ligand-binding domain (43)
. RXR serves as a permissive partner of PPARs. Although the effects of the PPAR subfamily on the lipid metabolism have been extensively studied, a proper examination of the role of PPARs in the transcriptional regulation of the Phase II detoxification genes has not been reported.
There are reports showing that PPAR
1 is expressed in the adipocytes and hepatic stellate cells with PPAR
2 being less frequently expressed (15
, 16
, 44)
. In the current study, it was shown that PPAR
1 was sufficiently expressed in the H4IIE and primary-cultured hepatocytes. It was revealed that either PPAR
or RXR agonist results in the induction of GSTA2 with increases in the mRNA and that treatment of the cells with the PPAR
and RXR agonists synergistically induces GSTA2. This was also observed in the cells treated with nanomolar concentrations of PGJ2 and RA. PGJ2 at nanomolar concentrations served as a ligand of PPAR
. Enhanced GSTA2 induction by PGJ2 + RA, compared with that by each agent alone, demonstrates that PPAR
and RXR heterodimer activation may contribute to the enzyme induction. This was further supported by the observation that the PPAR
ligand, troglitazone, rosiglitazone, or pioglitazone, in combination with RA, induced GSTA2 to a much greater extent. A discrepancy in the effective concentration range between PGJ2 (50 nM) and thiazolidinedione PPAR
agonist (110 µM) for GSTA2 induction may have resulted from the difference in their equilibrium dissociation rate constants for PPAR
. This is reflected by the high-affinity displacement of the binding of a radiolabeled thiazolidinedione to recombinant PPAR
by PGJ2 in a cell lysate system (45)
. Therefore, it is likely that PPAR
activation contributes to GSTA2 induction. Despite the weak induction of GSTA2 by RA alone, RA potentiated the enzyme induction by PPAR
agonist. These results suggested that ligand activation of RXR
is needed for the full responsiveness in GSTA2 induction by the PPAR
activator.
The expression of the Phase II detoxifying enzyme is transcriptionally activated partly through the activation of Nrf2 via the Nrf2 binding to the ARE in the promoter regions of the target genes (2
, 3)
. Nrf2 activation plays an important role in the induction of many Phase II detoxifying enzymes, and the lack of Nrf2/ARE activation increases the sensitivity to xenobiotics, including carcinogens (46, 47, 48)
. We reported previously that tert-butylhydroquinone, a representative prooxidant, activated Nrf2 for GSTA2 induction (9
, 49)
. In the current study, it was shown that either PGJ2 or RA alone at relatively high concentrations elicited Nrf2 translocation and its DNA binding in the H4IIE cells, whereas PGJ2 or RA at nanomolar concentrations required each other for Nrf2 activation. In addition, PGJ2 + RA induced Nrf2. We found that the promoter region of the Nrf2 gene contains the putative PPRE site (GenBank no. U70474, mouse Nrf2 promoter), which potentially interacts with the activating PPAR
RXR heterodimer. Therefore, both the presence of the binding sites for PPAR
RXR in the promoter region of the Nrf2 gene and the efficacious GSTA2 induction by nanomolar concentrations of PGJ2 and RA indicate that the PPAR
and RXR heterodimer activates the Nrf2 gene induction, which contributes to the GSTA2 induction.
Previous studies showed that cancer chemopreventive agents, including oltipraz and flavonoids, activate C/EBPß and stimulate C/EBPß binding to the C/EBP-response element in the GSTA2 gene (13
, 14)
. The essential role of the C/EBP-binding site in GSTA2 induction was further supported by an experiment using a dominant-negative mutant C/EBP (AC/EBP) in the reporter gene assay, which holds significant implication for the finding of C/EBPß as an important transcription factor for GSTA2 induction. The NH2-terminal transactivation domains of C/EBPß interact with CBP/p300 coactivator after binding to the C/EBP site, which is essential for C/EBPß-mediated gene transactivation (50)
. In the present study, it was observed that a combined treatment of the cells with either PGJ2 and RA induced the nuclear translocation of C/EBPß and activating C/EBPß binding to the C/EBP response element. In addition, PGJ2 + RA increased the C/EBPß expression level. The C/EBPß gene contains PPRE sites (GenBank no. AY056052). It is likely that C/EBPß induction via PPAR
and RXR
heterodimer binding to the PPREs in the promoter region of the C/EBPß gene is also responsible for inducing GSTA2.
This study provides evidence that both the ARE and C/EBP-binding site have essential roles in the transactivation of the GSTA2 gene by PPAR
and RXR ligands, as evidenced by the binding site-deleted promoterluciferase assay. The complete blockage of the PPAR
and RXR
-mediated induction of the GSTA2 gene as a result of a deletion mutation of either the ARE or C/EBP-binding site confirms the previous observation that the binding of Nrf2 and C/EBPß to their response elements is simultaneously necessary for the full gene transactivation (Fig. 12A
; Refs. 13
and 14
). It is inferred that the formation of the transcriptional protein complexes on the two essential binding sites is required for the full responsiveness to chemical inducers.
|
heterodimer activate transcription in response to the retinoic acid receptor-specific ligands on the DR5 elements but constitutively repress transcription on the DR1 elements (51)
. The PPAR
and PPAR
RXR
heterodimers have different DNA-binding specificities with preferential binding of the latter to DR1. The present finding of PPAR
and RXR heterodimer binding to the DR1 and functional role of the heterodimer in transactivating the GSTA2 gene excludes the possibility that the retinoic acid receptor-RXR heterodimer is involved in the transactivation of the GSTA2 gene. This is in parallel with the suppression of GSTP1 expression by RA in the presence of retinoic acid receptor as a result of the decreased transcription from its promoter (52)
. PGJ2 alone (at nanomolar concentrations) is a weak inducer of GSTA2, because the PPAR
RXR heterodimer requires the binding of an RXR ligand. The role of the PPAR
and RXR heterodimer in GSTA2 gene transactivation was confirmed by the comparable induction of GSTA2 by the thiazolidinedione PPAR
activator and RA. SRC-1 is a coactivator of PPAR
(53)
. Binding of the ligand-activated PPAR
RXR
heterodimer to its DNA-binding sites stimulates the interaction between PPAR
RXR
and p160/SRC-1 (53)
.
The observation that the ligand-activated PPAR
RXR heterodimer binds the regulatory PPREs independent of their activation and the induction of Nrf2 and C/EBPß led us to examine the functional role of each of these PPRE-binding sites containing the DRs related to the hexamer AGGTCA in the GSTA2 gene. Specific mutations of these nuclear binding sites in the GSTA2 promoter, which are present as a three PPRE cluster, resulted in the complete loss of its responsiveness to PGJ2 + RA. We showed that all of the putative PPRE sites comprising DR1 are functionally active. Therefore, the binding of the activating PPAR
RXR heterodimer to all of the PPRE sites is crucial for the inducible gene activation (Fig. 12B)
. Blockage of the ligand-dependent transcriptional response as a result of a mutation of the respective binding site suggests that the multiple putative PPREs function as a module in which the nuclear binding sites in close proximity to each other are essential for full ligand responsiveness. Therefore, it is highly likely that the PPAR-binding site cluster is the functionally active PPREM in the GSTA2 gene. Consistent with this, the essential role of the PPAR
RXR heterodimer and PPRE-binding elements in activation, the GSTA2 gene was further supported by the reporter gene induction experiments. It was observed that transcription of the GSTA2 gene was further enhanced by exposing the cells transfected with the plasmids encoding PPAR
and RXR
to their corresponding ligands. This study on the regulation of GSTA2 gene expression by the PPAR
RXR heterodimer at the promoter containing DR1 elements brings additional insights into the transcriptional control mechanism of the Phase II enzyme involved in carcinogen detoxification.
Nrf2 and C/EBPß play essential roles in gene transactivation. Now, we report that the activating PPAR
and RXR heterodimer functionally regulates PPREM activity via the proximal promoter of the GSTA2 gene and confers full responsiveness to the PPAR
and RXR ligands in association with the activating Nrf2 and C/EBPß (Fig. 12B)
. Both Nrf2 and C/EBPß are up-regulated in a PPAR
- and RXR-dependent manner. However, the induction of Nrf2 and C/EBPß resulted in little or no activation of the GSTA2 promoter in the cells transfected with a GSTA2 promoterreporter construct containing the sequentially mutated PPAR response elements. These results suggest that the PPAR response module, which was activated by the ligand-bound PPAR
and RXR heterodimer, may be essential for the formation of the transactivation complexes comprising Nrf2 and C/EBPß. The essential role of PPAR
binding to its target DNA element for enhancesome-mediated gene activation is further supported by the findings that activating transcription factors, such as PPAR
, Nrf2, and C/EBPß, form complexes with coregulators (e.g., CBP/p300; Ref. 53
) and that PPAR
binds to Nrf2 (54)
. An additional study revealed that PPAR
and RXR
agonists induced other forms of GST, including GSTA3 in H4IIE cells (data not shown). A search of the GenBank database showed that the putative PPRE containing DR1 element is located in the promoter region of the rat GSTA3 gene (GenBank no. AF067442). Therefore, the PPAR
RXR heterodimer may serve as a common transcriptional factor complex for inducing the GSTs in the liver.
In conclusion: (a) PPAR
agonist + RA both activate and induce Nrf2 and C/EBPß; (b) activating Nrf2 and C/EBPß binding to the antioxidant- and C/EBP-response elements stimulates the expression of the GSTA2 gene in response to the PPAR
and RXR agonists; (c) the promoter region of the GSTA2 gene contains the multiple PPRE cluster, which interacts with the PPAR
RXR heterodimer; and (d) the PPRE-binding sites present in the GSTA2 promoter might function as a PPREM for transactivation the GSTA2 gene. The fact that PPAR
RXR activation plays a key role in GST induction via direct gene transactivation, as well as the coordinate induction of the activating Nrf2 and C/EBPß, provides implication that dietary components, including fatty acids and retinoids, strongly affect GST regulation, whose transcription confers cancer chemoprevention, as well as the detoxification of xenobiotics and toxicants.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Requests for reprints: Sang Geon Kim, College of Pharmacy, Seoul National University, Sillim-dong, Kwanak-gu, Seoul 151-742, South Korea. Phone: 822-880-7840; Fax: 822-872-1795; E-mail: sgk{at}snu.ac.kr
Received 12/16/03. Revised 2/24/04. Accepted 3/ 4/04.
| REFERENCES |
|---|
|
|
|---|
contribute to growth hormone-regulated transcription of c-fos. J Biol Chem, 274: 31597-604, 1999.
and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet, 360: 1410-8, 2002.[CrossRef][Medline]
: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology, 135: 798-800, 1994.[Abstract]
-mediated transcriptional up-regulation of the hepatocyte growth factor gene promoter via a novel composite cis-acting element. J Biol Chem, 276: 25049-56, 2001.
-mediated gene expression: a new mechanism of action for high density lipoprotein. J Biol Chem, 227: 23582-6, 2002.
modulators (SPARMs). Trends Mol Med, 7: 395-400, 2001.[CrossRef][Medline]
. Mol Cell, 1: 465-70, 1998.[CrossRef][Medline]
. Nat Med, 4: 1046-52, 1998.[CrossRef][Medline]
ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA, 96: 3951-6, 1999.
associated with human colon cancer. Mol Cell, 3: 799-804, 1999.[CrossRef][Medline]
2 versus PPAR
1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem, 272: 8071-6, 1997.
, and microsomal glutathione S-transferase in CYP2E1 overexpressing HepG2 cells and protection against short-term oxidative stress. Hepatology, 33: 652-61, 2001.[CrossRef][Medline]
. J Pharmacol Exp Ther, 284: 751-9, 1998.
with transcriptional coactivators. J Biol Chem, 275: 33201-4, 2000.
in macrophages via an interaction with Nrf2. J Biol Chem, 275: 33142-50, 2000.This article has been cited by other articles:
![]() |
H. Gong, J. He, J. H. Lee, E. Mallick, X. Gao, S. Li, G. E. Homanics, and W. Xie Activation of the Liver X Receptor Prevents Lipopolysaccharide-induced Lung Injury J. Biol. Chem., October 30, 2009; 284(44): 30113 - 30121. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhao, R. Strong, J. Zhang, G. Sun, J. Z. Tsien, Z. Cui, J. C. Grotta, and J. Aronowski Neuronal PPAR{gamma} Deficiency Increases Susceptibility to Brain Damage after Cerebral Ischemia J. Neurosci., May 13, 2009; 29(19): 6186 - 6195. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. T. Tran, L. Xu, V. Phan, S. B. Goodwin, M. Rahman, V. X. Jin, C. H. Sutter, B. D. Roebuck, T. W. Kensler, E.O. George, et al. Chemical genomics of cancer chemopreventive dithiolethiones Carcinogenesis, March 1, 2009; 30(3): 480 - 486. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Ondrey Peroxisome Proliferator-Activated Receptor {gamma} Pathway Targeting in Carcinogenesis: Implications for Chemoprevention Clin. Cancer Res., January 1, 2009; 15(1): 2 - 8. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Katzenellenbogen, L. Mizrahi, O. Pappo, N. Klopstock, D. Olam, J. Jacob-Hirsch, N. Amariglio, G. Rechavi, E. Domany, E. Galun, et al. Molecular Mechanisms of Liver Carcinogenesis in the Mdr2-Knockout Mice Mol. Cancer Res., November 1, 2007; 5(11): 1159 - 1170. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Kronke, A. Kadl, E. Ikonomu, S. Bluml, A. Furnkranz, I. J. Sarembock, V. N. Bochkov, M. Exner, B. R. Binder, and N. Leitinger Expression of Heme Oxygenase-1 in Human Vascular Cells Is Regulated by Peroxisome Proliferator-Activated Receptors Arterioscler Thromb Vasc Biol, June 1, 2007; 27(6): 1276 - 1282. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-S. Kim, S. M. Lee, W. D. Kim, S. H. Ki, A. Moon, C. H. Lee, and S. G. Kim G{alpha}12/13 Basally Regulates p53 through Mdm4 Expression Mol. Cancer Res., May 1, 2007; 5(5): 473 - 484. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Kim and S. J. Lee PI3K, RSK, and mTOR Signal Networks for the GST Gene Regulation Toxicol. Sci., April 1, 2007; 96(2): 206 - 213. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Ko, S. J. Lee, J. W. Kim, J. W. Lim, and S. G. Kim DIFFERENTIAL EFFECTS OF THE OXIDIZED METABOLITES OF OLTIPRAZ ON THE ACTIVATION OF CCAAT/ENHANCER BINDING PROTEIN-{beta} AND NF-E2-RELATED FACTOR-2 FOR GSTA2 GENE INDUCTION Drug Metab. Dispos., August 1, 2006; 34(8): 1353 - 1360. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Lee, E. K. Yang, and S. G. Kim Peroxisome Proliferator-Activated Receptor-{gamma} and Retinoic Acid X Receptor {alpha} Represses the TGFbeta1 Gene via PTEN-Mediated p70 Ribosomal S6 Kinase-1 Inhibition: Role for Zf9 Dephosphorylation Mol. Pharmacol., July 1, 2006; 70(1): 415 - 425. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Katzenellenbogen, O. Pappo, H. Barash, N. Klopstock, L. Mizrahi, D. Olam, J. Jacob-Hirsch, N. Amariglio, G. Rechavi, L. A. Mitchell, et al. Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the mdr2-knockout mice. Cancer Res., April 15, 2006; 66(8): 4001 - 4010. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Gong, S. V. Singh, S. P. Singh, Y. Mu, J. H. Lee, S. P. S. Saini, D. Toma, S. Ren, V. E. Kagan, B. W. Day, et al. Orphan Nuclear Receptor Pregnane X Receptor Sensitizes Oxidative Stress Responses in Transgenic Mice and Cancerous Cells Mol. Endocrinol., February 1, 2006; 20(2): 279 - 290. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Lee and S. G. Kim Role of p90 Ribosomal S6-Kinase-1 in Oltipraz-Induced Specific Phosphorylation of CCAAT/Enhancer Binding Protein-beta for GSTA2 Gene Transactivation Mol. Pharmacol., January 1, 2006; 69(1): 385 - 396. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Dai, N. Chou, L. He, M. A. Gyamfi, A. J. Mendy, A. L. Slitt, C. D. Klaassen, and Y.-J. Y. Wan Retinoid X Receptor {alpha} Regulates the Expression of Glutathione S-transferase Genes and Modulates Acetaminophen-Glutathione Conjugation in Mouse Liver Mol. Pharmacol., December 1, 2005; 68(6): 1590 - 1596. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Bae and S. G. Kim Enhanced CCAAT/Enhancer-Binding Protein {beta}-Liver-Enriched Inhibitory Protein Production by Oltipraz, Which Accompanies CUG Repeat-Binding Protein-1 (CUGBP1) RNA-Binding Protein Activation, Leads to Inhibition of Preadipocyte Differentiation Mol. Pharmacol., September 1, 2005; 68(3): 660 - 669. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Ki, I. J. Cho, D. W. Choi, and S. G. Kim Glucocorticoid Receptor (GR)-Associated SMRT Binding to C/EBP{beta} TAD and Nrf2 Neh4/5: Role of SMRT Recruited to GR in GSTA2 Gene Repression Mol. Cell. Biol., May 15, 2005; 25(10): 4150 - 4165. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Avis, A. Martinez, J. Tauler, E. Zudaire, A. Mayburd, R. Abu-Ghazaleh, F. Ondrey, and J. L. Mulshine Inhibitors of the Arachidonic Acid Pathway and Peroxisome Proliferator-Activated Receptor Ligands Have Superadditive Effects on Lung Cancer Growth Inhibition Cancer Res., May 15, 2005; 65(10): 4181 - 4190. [Abstract] [Full Text] [PDF] |
||||
![]() |
I-N. Park, I. J. Cho, and S. G. Kim CERAMIDE, AN APOPTOTIC RHEOSTAT, INHIBITS CCAAT/ENHANCER BINDING PROTEIN-{beta} AND NF-E2-RELATED FACTOR-2 ACTIVATION: THE ROLE IN GLUTATHIONE S-TRANSFERASE A2 GENE REPRESSION Drug Metab. Dispos., September 1, 2004; 32(9): 893 - 897. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |